US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

BIOC

Biocept (BIOC)

Biocept Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BIOC

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/10/20	19 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIOC	Biocept Inc
2023/10/16	21 : 53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIOC	Biocept Inc
2023/09/21	21 : 00	Business Wire	Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases	NASDAQ:BIOC	Biocept Inc
2023/09/08	21 : 00	Business Wire	Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics	NASDAQ:BIOC	Biocept Inc
2023/09/05	21 : 00	Business Wire	Biocept to Participate in the H.C. Wainwright Global Investment Conference	NASDAQ:BIOC	Biocept Inc
2023/08/25	21 : 00	Business Wire	Biocept to Hold Business Update Conference Call on August 30, 2023	NASDAQ:BIOC	Biocept Inc
2023/08/23	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIOC	Biocept Inc
2023/08/15	05 : 05	Business Wire	Biocept Reports Second Quarter 2023 Financial Results	NASDAQ:BIOC	Biocept Inc
2023/08/14	21 : 00	Business Wire	Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference	NASDAQ:BIOC	Biocept Inc
2023/07/14	07 : 15	Business Wire	Biocept Announces the Passing of Board Chair M. Faye Wilson	NASDAQ:BIOC	Biocept Inc
2023/06/22	05 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BIOC	Biocept Inc
2023/06/21	08 : 10	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:BIOC	Biocept Inc
2023/06/21	05 : 15	Business Wire	Biocept Names Antonino Morales as President and Chief Executive Officer	NASDAQ:BIOC	Biocept Inc
2023/06/15	05 : 05	Business Wire	Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023	NASDAQ:BIOC	Biocept Inc
2023/06/05	21 : 00	Business Wire	Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology	NASDAQ:BIOC	Biocept Inc
2023/05/25	19 : 04	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:BIOC	Biocept Inc
2023/05/25	09 : 39	Business Wire	Biocept Announces Pricing of $5.0 Million Underwritten Public Offering	NASDAQ:BIOC	Biocept Inc
2023/05/23	21 : 18	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:BIOC	Biocept Inc
2023/05/17	21 : 00	Business Wire	Biocept Announces One-for-Thirty Reverse Stock Split	NASDAQ:BIOC	Biocept Inc
2023/05/17	05 : 12	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:BIOC	Biocept Inc
2023/05/15	20 : 01	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:BIOC	Biocept Inc
2023/05/15	19 : 29	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BIOC	Biocept Inc
2023/05/11	05 : 05	Business Wire	Biocept Reports First Quarter 2023 Financial Results	NASDAQ:BIOC	Biocept Inc
2023/04/21	21 : 31	Edgar (US Regulatory)	Revised Proxy Soliciting Materials (definitive) (defr14a)	NASDAQ:BIOC	Biocept Inc
2023/04/21	05 : 07	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:BIOC	Biocept Inc
2023/04/18	05 : 47	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BIOC	Biocept Inc
2023/04/18	05 : 10	Business Wire	Biocept Reports 2022 Financial Results	NASDAQ:BIOC	Biocept Inc
2023/04/18	05 : 04	Edgar (US Regulatory)	Amended Quarterly Report (10-q/a)	NASDAQ:BIOC	Biocept Inc
2023/04/17	21 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BIOC	Biocept Inc
2023/04/11	05 : 06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BIOC	Biocept Inc

Showing the most relevant articles for your search:NASDAQ:BIOC

1 2 3 4 5 6 7 8 9 10 次へ >>

Vontobel Financial Produ...

Romania Tf 2,75% Fb26 Eur

Zoom Video Communications

Zaio Corporation

Jpmorgan Chase Financial...

Republic of France

PepinNini Minerals

LOG Commercial ON

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約